BioTelemetry, Inc. Names Dr. Andrei Stoica Chief Technology Officer

MALVERN, Pa., April 07, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Dr. Andrei Stoica has been named Chief Technology Officer of the company.  Dr. Stoica will lead the company’s global technology and product development operations, reporting to Joseph H. Capper, President and Chief Executive Officer.
“We are delighted to welcome Andrei to our BioTelemetry team during this transformational time of growth and innovation,” said Joseph H. Capper, President and Chief Executive Officer of BioTelemetry.  “His extensive expertise in enterprise technology solutions, including cloud platforms, information security, and software and product development, will be instrumental as we continue to create best-in-class solutions across our product and service offerings.”   Since 2006, Dr. Stoica held various leadership positions at IQVIA, most recently serving as its SVP, IT Systems Development, leading the development of the global data and AI/ML cloud platform.  His appointments prior to IQVIA include information technology positions in the health IT industry as well as research and teaching positions in academia.  Dr. Stoica holds a Ph.D. in Computer Science and Engineering from the University of South Carolina.  He has served on multiple committees and authored numerous papers, and has been recognized and awarded for his use of technology innovation to evolve enterprise IT.“This is an exciting time for BioTelemetry, and I am looking forward to working with a team that shares my passion for leveraging technology and innovation to address today’s healthcare challenges and save lives,” said Dr. Stoica.  “BioTelemetry is an established leader in connected health, and we are uniquely positioned to offer a continuum of solutions that truly makes a difference for our patients and customers.  Our IoT cloud platform and clinical subject matter expertise already provides a differentiating capability to aid physicians in making informed decisions about patient treatments, and our platforms will constantly improve powered by AI/ML technologies.”About BioTelemetryBioTelemetry, Inc. is the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, centralized core lab services for clinical trials, remote blood glucose monitoring, and original equipment manufacturing that serves both healthcare and clinical research customers.  More information can be found at www.gobio.com.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.